Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could shrinking radiation targets improve life for brain cancer patients?

NCT ID NCT06719440

Disease control Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

The BELGICA trial is testing whether giving radiation in a more focused way to people with glioblastoma can reduce side effects and improve quality of life without shortening survival. About 347 newly diagnosed patients will be randomly assigned to receive either standard or reduced radiation margins around the tumor. The study aims to find a safer way to deliver radiotherapy while maintaining its effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiotherapy
What this could lead to
If successful, this could lead to a new standard of care that reduces brain radiation side effects and improves quality of life for glioblastoma patients.
What could go wrong
This is a Phase NA trial with 347 participants. The smaller radiation field might not control the tumor as well, potentially reducing survival. Results are not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 347 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Oct 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants capable of giving informed consent * Age \>= 18 y.o. * WHO performance status 0-2 * Newly diagnosed glioblastoma (Histologically proven glioblastoma per WHO 2021 classification based on biopsy or resection ) * Indication of chemoradiotherapy confirmed by multidisciplinary tumour board Exclusion Criteria: * Participation in a competing trial * Known contraindication to undergo MRI scans

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glioblastoma radiation injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glioblastoma Radiotherapy side effect

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    23 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AZ Delta

    RECRUITING

    Roeselare, 8800, Belgium

  • AZ Groeninge

    RECRUITING

    Kortrijk, 8500, Belgium

  • AZ Sint Jan

    RECRUITING

    Bruges, 8000, Belgium

  • AZ Sint Maarten

    RECRUITING

    Mechelen, 2800, Belgium

  • AZ Sint-Lucas

    RECRUITING

    Ghent, 9000, Belgium

  • CH Mouscron

    NOT_YET_RECRUITING

    Mouscron, 7700, Belgium

  • CHR Verviers

    RECRUITING

    Verviers, 4800, Belgium

  • CHU Liège

    RECRUITING

    Liège, 4000, Belgium

  • CHU UCL Namur - Sainte Elisabeth

    RECRUITING

    Namur, 5000, Belgium

  • Chu Helora

    RECRUITING

    La Louvière, 7100, Belgium

  • Cliniques de l'Europe

    RECRUITING

    Uccle, 1180, Belgium

  • Cliniques universitaires Saint-Luc

    RECRUITING

    Brussels, 1200, Belgium

  • EpiCURA

    RECRUITING

    Baudour, 7331, Belgium

  • Grand Hôpital de Charleroi

    RECRUITING

    Gilly, 6060, Belgium

  • Hôpital André Vésale - HUmani

    RECRUITING

    Montigny-le-Tilleul, 6110, Belgium

  • Institut Jules Bordet

    NOT_YET_RECRUITING

    Brussels, 1070, Belgium

  • JESSA Ziekenhuis

    RECRUITING

    Hasselt, 3500, Belgium

  • Olv Azorg

    NOT_YET_RECRUITING

    Aalst, 9300, Belgium

  • UZ Brussel

    NOT_YET_RECRUITING

    Brussels, 1090, Belgium

  • UZ Gent

    NOT_YET_RECRUITING

    Ghent, 9000, Belgium

  • UZ Leuven

    RECRUITING

    Leuven, 3000, Belgium

  • ZAS Augustinus

    RECRUITING

    Wilrijk, 2610, Belgium

  • Ziekenhuis Oost-Limburg (ZOL)

    RECRUITING

    Genk, 3600, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.